HCFA denial of AWP payments upheld
Fifth Circuit Court affirmed Health Care Financing Administration disapproval of Louisiana Medicaid agency drug reimbursements based on published average wholesale prices. HCFA "could disapprove" state payments, "even though Louisiana proved that its cost calculation method would not result in reimbursement" exceeding aggregate upper limits set by Medicaid regs of 1987. Louisiana had appealed HCFA's disapproval. However, the appellate court said its decision does not permit HCFA to impose uniform AWP-minus discount payments without notice and comment. It added that Louisiana would have prevailed "had it been able to prove that AWP did provide the closest" estimated acquisition cost.
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.